Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Helix BioPharma Corp.
DescriptionAntibody DOS47 conjugate that targets vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2; KDR/Flk-1)
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat breast cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today